Blog, Noticias

Journal of Alzheimer’s Disease 2014

Posted by:

Alvarez XA, Aleixandre M, Linares C, Masliah E, Moessler H. Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer’s disease. Journal of Alzheimer’s Disease 2014; 42:1347-1355

Continúe Leyendo →
0

Future Neurology 2013

Posted by:

Alvarez XA, Figueroa J, Muresanu D. Peptidergic drugs for treatment of traumatic brain injury. Future Neurology 2013;8(2):175–192

Continúe Leyendo →
0

European Neurological Review 2012

Posted by:

Alvarez XA, Linares C, Masliah E. Combination drug therapy for the treatment of Alzheimer’s disease. European Neurological Review 2012;7(2):92–102

Continúe Leyendo →
0

Drugs Today 2011

Posted by:

Alvarez XA, Fuentes P. Cerebrolysin in Alzheimer’s disease. Drugs Today 2011;47(7):487-513.

Continúe Leyendo →
0

J Neurosci Res 2011

Posted by:

Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease. J Neurosci Res 2011;89(11):1812-21.

Continúe Leyendo →
0

Eur J Neurology 2011

Posted by:

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer_s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurology 2011;18:59-68.

Continúe Leyendo →
0

Current Alzheimer Research 2011

Posted by:

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, Linares C, Granizo E, García-Fantini M, Beurecht W, Doppler E, Moessler H. Combination Treatment in Alzheimer’s Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. Current Alzheimer Research 2011; 8:593-591

Continúe Leyendo →
0

J Neurol Sci 2010

Posted by:

Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci 2010;299(1-2):179-183.

Continúe Leyendo →
0

Pharmaceuticals 2010

Posted by:

Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, Corzo L, Carrera I, Tellado I, Nebril L, Alcaraz M, Rodriguez S, Casas A, Couceiro V, Alvarez A. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals 2010;3(10):3040-3100.

Continúe Leyendo →
0

Int J Neuropsychopharmacol 2009

Posted by:

Alvarez, XA, Sampedro, C., Cacabelos, R., Linares, C., Aleixandre, M., García-Fantini, M., Moessler, H. Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer patients treated with the neurotrophic agent Cerebrolysin. Int J Neuropsychopharmacol 2009;12:867-872

Continúe Leyendo →
0
Page 2 of 2 12